

SUPPLEMENTARY MATERIAL

Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges

Haitham Salem^{a,b}, Caesa Nagpal^b, Teresa Pigott^b and Antonio Lucio Teixeira^{a,b,*}

^aNeuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA; ^bHarris County Psychiatric Center, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA

Supplementary Table 1. Ongoing clinical trials on akathisia management as listed on the clinicaltrials.gov website.

	Study	Drug	Design/type	Classification	Estimated Enrollment/ Follow-up Period	Outcomes
1	NCT00693472	Preladenant	Randomized/ Interventional Double blind	Exploratory Efficacy (Phase II)	46/ 13 days	Completed with no published results
2	NCT00065286	Neuroleptics	Observational/ Longitudinal	Phase III	Not specified/ 6months	Completed with no published results
3	NCT01051271	Midazolam	Randomized/ Interventional Double blind	Phase II/Phase III	225/ 15 minutes	Completed with no published results
4	NCT01069536	Metoclopramide	Randomized/ Interventional Double blind	Phase III	140/ 2 and 15 minutes	Completed with no published results
5	NCT01942343	Droperidol Ondansetron	Randomized/ Interventional Double blind	Phase III	300/ 1 day	Not yet recruiting
6	NCT00659919	Trazodone	Randomized/ Interventional Double blind	Phase IV	13/ 3 days	Completed with no published results
7	NCT00475306	Metoclopramide Diphenhydramine	Randomized/ Interventional Double blind	Phase IV	289/ 60 minutes	Preliminary outcomes show lower levels of akathisia upon combination of metoclopramide with Diphenhydramine
8	NCT00892047	Venlafaxine XR plus Aripiprazole	Randomized/ Interventional Double blind	Phase IV	468/ 12 weeks	Lenze <i>et al.</i> , 2015
9	NCT00686699	Preladenant	Randomized/ Interventional Double blind	Exploratory Efficacy (Phase II)	11/ 6 hours and 14 days	Terminated
10	NCT00403546	Geodon	Randomized/ Interventional Double blind	Phase III	80/ 8 weeks	Completed with no published results

11	NCT00772005	Armodafinil	Randomized/ Interventional Double blind	Exploratory Efficacy (Phase II)	287/ 24 weeks	Kane <i>et al.</i> , 2012
12	NCT01457339	SPD489 (Lisdexamfetamine dimesylate)	Randomized/ Interventional Double blind	Phase I	31/ 5 days	Completed with no published results
13	NCT00261443	Aripiprazole	Randomized/ Interventional Double blind	Phase IV	1270/52 weeks	Marcus <i>et al.</i> , 2011
14	NCT01438060	Aripiprazole	Randomized/ Interventional Double blind	Phase III	232/ 10 weeks	Completed with no published results
15	NCT00190749	Olanzapine	Randomized/ Interventional Double blind	Phase IV	130/ 12 weeks	Case <i>et al.</i> , 2010
16	NCT01760993	SPD489	Study safety/ Open label/ Interventional single group assignment	Phase III	2/52 weeks	Terminated
17	NCT01670279	Brexpiprazole	Randomized/ Interventional Double blind	Phase I	18/ 45 days	Completed with no published results
18	NCT01909466	Aripiprazole, OPC- 14597	Study safety/ Open label/ Interventional	Phase I	141/ 20 weeks	Completed with no published results
19	NCT00227305	Quetiapine fumarate	Study safety/ Open label/ Interventional	Phase III	381/ 26 weeks	Finding <i>et al.</i> , 2013
20	NCT02435836	Aripiprazole	Study safety/ Open label/ Interventional	Phase III	631/ 108 weeks then every 12 weeks	Terminated